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http://www.biomedcentral.com/1471-2121/13/27RESEARCH ARTICLE Open AccessPhosphorylation of P68 RNA Helicase by P38 MAP
kinase contributes to colon cancer cells apoptosis
induced by oxaliplatin
Heena Dey and Zhi-Ren Liu*Abstract
Background: We previously demonstrated that p68 phosphorylation at threonine residues correlates with cancer
cell apoptosis under the treatments of TNF-α and TRAIL (Yang, L. Mol Cancer Res Vol 3, pp 355–63 2005).
Results: In this report, we characterized the role of p68 phosphorylation in apoptosis induction under the
treatment of oxaliplatin in the colon cancer cells. Our data suggest that oxaliplatin treatment activates p38 MAP
kinase, which subsequently phosphorylates p68 at T564 and/or T446. The phosphorylation of p68, at least partially,
mediates the effects of the drug on apoptosis induction, as mutations at these two sites greatly reduce the cancer
cell death.
Conclusion: Our studies reveal an important molecular mechanism that mediates the effects of anti-cancer drug,
providing a potential strategy for improving cancer treatment.
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Oxaliplatin is a new generation of platinum derivatives
that is currently used in the front line for the treatment
of human colorectal cancer and other cancers [1]. The
therapeutic effects of oxaliplatin may result from the
DNA damage caused by the compound, which lead to
cell cycle arrest and apoptosis [2,3]. The compound can
induce DNA damage by the formation of cross-links be-
tween the two strands of DNA, leading to blockage of
DNA replication and transcription [3-5]. The compound
activates multiple signaling pathways in mediating apop-
tosis induction [6,7]. It is known that treatment of can-
cer cells with oxaliplatin results in the activation of p38
and/or JNK kinases, which subsequently target a number
of downstream effector molecules leading to cell apop-
tosis. Although the mechanism underlying the tumor
apoptosis induced by the drug has been intensively stud-
ied, the detailed mechanism, especially the cellular mole-
cules that contribute to the effects of the drug, is not
fully understood.* Correspondence: zliu8@gsu.edu
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reproduction in any medium, provided the orP38 is a stress-activated MAP kinase that is activated
in response to many cellular stress induction signals, in-
cluding oxidative stress and toxic chemicals [8,9]. Sus-
tained activation of p38 MAP kinase is critical in
mediating the effects of the stress signals in the induc-
tion of cell apoptosis [10,11]. A number of anti-cancer
agents act via activation of p38, such as platinum com-
pounds [12], etoposide [13], and taxol [14]. P38 Map
kinase is activated by phosphorylation at Thr180 and
Tyr182 residues in its conserved TGY motif [15,16]. The
p38 MAP kinase targets a number of very important
downstream proteins to exert its effects in apoptosis in-
duction. It is reported that phosphorylation of p53 on
Ser46 by p38 is essential for apoptosis induction by sev-
eral anti-cancer drugs and virus [17,18]. Treatment of
colon cancer cells with oxaliplatin leads to activation of
p38 MAP kinase, which subsequently phosphorylates
gamma-H2AX and securin. These phosphorylation
events contribute to the cell apoptosis induced by the
compound [19,20].
The nuclear p68 RNA helicase is a member of the
DEAD box family of RNA helicase [21,22]. P68 RNA
helicase plays a very important role in cell proliferation
and early organ development and maturation [23]. TheLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumor progression and transformation [24]. We have
previously reported that p68 RNA helicase is phosphory-
lated at multiple amino acid residues, including serine/
threonine and tyrosine [25]. P68 was phosphorylated at
tyrosine residue(s) in a number of different cancer cell
lines but not in the corresponding normal cells/tissues.
In response to growth factor PDGF-BB stimulation, p68
is phosphorylated at Y593 by c-Abl in HT-29 cells. Phos-
phorylation of p68 at Y593 promotes EMT via promot-
ing β-catenin nuclear translocation [26]. P68 acquires a
double tyrosine phosphorylation at Y593/Y595 in T98G
glioblastoma cells. The double phosphorylation mediates
resistance to TRAIL-induced apoptosis. Interestingly,
when the cancer cells become apoptotic resistant, double
tyrosine phosphorylations of p68 increases while threo-
nine phosphorylation of p68 decreases indicating that
p68 threonine phosphorylation may play an important
role in mediating the effects of anti-cancer drug in the
induction of apoptosis [25]. We report here that, upon
the anti-cancer drug oxaliplatin treatment, p68 RNA
helicase becomes threonine phosphorylated in colon
cancer HCT116 cells. Oxaliplatin treatment activates
p38 MAP kinase in the cells, which subsequently phos-
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Figure 1 Threonine phosphorylation of p68 in HCT116 cells under ox
treatment of different concentrations of oxaliplatin is measured by a comm
the apoptosis of the cells without oxaliplatin treatment as 1. Error bars repr
and (D) Threonine phosphorylations of p68 in HCT116 cells that are treated
oxaliplatin for different times (D) are analyzed by immunobloting the p68 t
against phorsphor-threonine (IB:14B3). Immunoblot of p68 (IB:p68) in immu
In (C), the analyses are carried out with the cells that are already floating (F
treatments.demonstrate that the phosphorylation of p68 at T564
and/or T446 is critically important for the apoptosis in-
duction by the drug. Our studies reveal a very important
molecular factor that mediates the effects of anti-cancer
drug in apoptosis induction and may suggest a potential
therapeutic strategy for cancer treatment.
Results
Oxaliplatin treatment of colon cancer cells induced p68
threonine phosphorylation
We previously reported that tyrosine phosphorylation of
p68 correlates with tumor progression [25]. In studying
the effects of several anti-cancer drugs and p68 phos-
phorylation status, we noted that significantly higher
levels of p68 threonine phosphorylation were observed
in the colon cancer cells following the treatment with
several anti-cancer drugs [25]. We asked whether the
phosphorylation of p68 at threonine plays a role in me-
diating the anti-cancer drug effects. We used oxaliplatin
that is commonly used in the treatment of colon cancer
patients. Massive cell death of HCT116 cells was
induced upon the treatment with the drug at different
dosages (Figure 1A). We then examined the threonine
phosphorylation of p68 by the procedure similar to that
described in our previous reports [25,27]. It was clearB














aliplatin (Oxa) treatment. (A) Apoptosis of HCT116 cells under the
ercial apoptosis kit and presented as Relative apoptosis by defining
esent standard deviations of four independent experiments. (B), (C),
with different concentrations of oxaliplatin (B) and (C) or 20 μM of
hat is immunoiprecipitated (IP:p68) from cell lysates using antibody
noprecipitates indicate the amounts of p68 were precipitated down.
loating) and the cells that are still adherent (Adherent) under the
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phosphorylation at threonine (Figure 1B). This phos-
phorylation increase was observed with both the floating
cells and the cells that were still attached to the culture
plate under the drug treatment (Figure 1C). We subse-
quently tested the timing of the p68 threonine phos-
phorylation upon oxaliplatin treatment. It was evident
that the p68 threonine phosphorylation reached a peak
around 4 – 6 hours post drug treatment at the most
commonly used drug concentration of 20 μM. The
phosphorylation decreased thereafter (Figure 1D).
P68 is phosphorylated by p38 MAP kinase at T564 and
T446 upon the drug treatment
We next sought to investigate the protein kinase that
phosphorylates p68 in response to the anti-cancer drug
treatment. It is well known that p38 MAP kinase is
strongly activated in colon cancer cells upon the treatment
















Figure 2 MAPKPhosphorylation of p68 by p38 MAPK. (A) Threonine ph
oxaliplatin for different times are analyzed by immunobloting the p68 that
against phorsphor-threonine (IB:14B3). Phosphorylation of p38 MAPK under
antibody against the phosphorylated p38. Immunoblot of p68 (IB:p68) in th
precipitated. Immunoblot of p38 in the cell lysate (IB:p38) indicate the cellu
p38 and p68 in the cell extracts of HCT116 cells with/without oxaliplatin tr
immunoprecipitates (IP:p68) using antibody against p38 (IB:p38). Immunob
p68 that are precipitated. IP:IgG is the immunoprecipitation using rabbit Ig
His-p68 or BSA, as a control, by recombinant p38 in the presence of [γ-32P]
the phosphorylation reactions are shown by coomasie blue stains (CBS). (D
MAPK, wild type and constitutively active mutant D176A-F327L, in HCT116
immunoiprecipitated (IP:p68) from cell lysates using antibody against phors
immunoprecipitates indicate the amounts of p68 that are precipitated. Imm
Immunoblot of GAPDH (IB:GAPDH) is a loading control.the induction of apoptosis of the cancer cells [11,28]. To
investigate the relation of p68 threonine phosphorylation
and p38 MAP kinase activation, we simultaneously probed
p68 phosphorylation and phosphorylation of p38 MAP
kinase at the TGY motif using a commercially available
antibody against the phosphorylated/activated p38 in
HCT116 cells. It was clear that p38 MAP kinase was acti-
vated upon the oxaliplatin treatment. Interestingly, the
timing of p38 MAP kinase activation/phosphorylation cor-
related very well with the p68 phosphorylation at threo-
nine upon the oxaliplatin treatment (Figure 2A),
indicating a possibility that p68 is a target of p38 MAP
kinase during the induction of cell apoptosis by the anti-
cancer drug. To test whether p68 is indeed the target of
p38 MAP kinase, we examined the interaction of p68 and
p38 by co-immunoprecipitation. HCT116 cells expressing
endogenous p68 and p38 were treated by oxaliplatin. P68
was immunoprecipitated from the cell extracts prepared
from the treated cells using anti-p68 antibody. It wasB
IB: p38
Oxa - +      +












osphorylations of p68 in HCT116 cells that are treated with 20 μM of
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the same treatment is analyzed by immunoblot of cell lysates using
e immunoprecipitates indicate the amounts of p68 that are
lar levels of p38, as a loading control. (B) Co-immunoprecipitation of
eatment (Oxa, +/− 20 μM) was analyzed by immunoblot of p68
lot of p68 (IB:p68) in the immunoprecipitates indicate the amounts of
G, serving as a negative control IP. (C) Phosphorylation of recombinant
-ATP is revealed by autoradiography. The amounts of proteins used in
) Phosphorylation of p68 by exogenous expression of Flag-tagged p38
cells are analyzed by immunoblotting the p68 that are
phor-threonine (IB:14B3). Immunoblot of p68 (IB:p68) in
unoblot of Flag-tag (IB:FLAG) indicate the exogenous p38 levels.
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(Figure 2B). We then further verified the phosphorylation
of p68 by p38 MAP kinase by carrying out an in vitro
phosphorylation using recombinant p68 and p38 MAP
kinase. It was clear that the recombinant p68 was phos-
phorylated by the recombinant p38. As a control, BSA
was not phosphorylated by the recombinant MAP kinase
(Figure 2C). To further confirm that p38 indeed phos-
phorylated p68 at threonine residue, we used a constitu-
tively activated p38 mutant D176A-F327L. D176A-F327L
was expressed in HCT cells. Phosphorylation of p68 at
threonine residue(s) in cells was examined by the immu-
noprecipitation and immunoblot procedures. Apparently,
phosphorylation of p68 at threonine was dramatically
increased upon the p38 mutant expression (Figure 2D).
We concluded from our studies that p68 is phosphory-
lated by p38 MAP kinase upon the apoptosis induction by
anti-cancer drug treatment.
We next determined the potential p68 phosphoryl-
ation sites by p38 MAP kinase. We carried out a phos-
phorylation site search using a web-based program. TheMEF2C Q S L  A    T      P   V V S
MAPKAPK2      K V P Q    T      P   L H T A
A
ATF-2 D  Q T P    T      P   T R F
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Figure 3 Phosphorylation site(s) of p68 by p38 MAPK. (A) Prediction o
and compared to the consensus p38 MAPK phosphorylation sites of severa
prediction program NetPhos 2.0, (B) Phosphorylation of recombinant His-p
mutations (Lower) by recombinant p38 in the presence of [γ-32P]-ATP is rev
phosphorylation reactions are shown by coomasie blue stains (CBS). (C) Ph
mutants (Single site mutation, Upper, and Double site mutations, Lower), in
analyzed by immunoblotting the p68 that is immunoiprecipitated (IP:p68)
Immunoblot of p68 (IB:p68) in immunoprecipitates indicate the amounts oconsensus phosphorylation site search indicated several
potential S/T phosphorylation sites (Figure 3A). Based
on the phosphorylation site prediction, we made several
mutants that carried mutation at the predicted phos-
phorylation sites (Figure 3A). In vitro phosphorylation
reaction with the generated mutants using the recom-
binant p38 indicated that there was a significant de-
crease in p68 phosphorylation with the mutant T564A,
while there was almost no change with other mutants
(Figure 3B, Upper panel), indicating that T564 is a po-
tential site. To verify whether the T564 is the phosphor-
ylation site, the T564A mutant or other mutants were
expressed in HCT116 cells. After the cells were treated
with oxaliplatin, phosphorylation of the p68 mutant at
threonine was examined. Surprisingly, there was no
change in p68 threonine phosphorylation with wild type
and any mutant (Figure 3C Upper panel). One possible
explanation is that p68 may have additional phosphoryl-
ation sites by p38 MAP kinase. It is well established that
p38 MAP kinase often phosphorylates multiple sites in
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ealed by autoradiography. The amounts of proteins used in the
osphorylation of exogenously expressed HA-p68s, wild type (WT) and
HCT116 cells with/without oxaliplatin treatment (Oxa, +/−) are
from cell lysates using antibody against phorsphor-theronine (IB:14B3).
f p68 that are precipitated.
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in vitro phosphorylation was carried out with these two
mutants. It was clear that phosphorylation of T564/
446A by p38 MAP kinase was almost abolished, while
the phosphorylation of T446/224A had very minor re-
duction (Figure 3B Lower panel). The in vitro phosphor-
ylation results suggested that it is likely that the T564
and T446 of p68 are the phosphorylation sites by p38.
To verify whether indeed the T564 and T446 are the
phosphorylation sites, HA-tagged p68 wt, T564/446A,
and T446/T224A were expressed in HCT116 cells. The
cells were treated by oxaliplatin. Phosphorylations of the
HA-tagged p68 wt and the mutants were examined.
Clearly, phosphorylation of T446/T224A experienced a
minor decrease, while phosphorylation of T564/446A
was almost abolished (Figure 3C Lower panel). The
results strongly argued that p38 phosphorylated p68 at
T564 and T446 upon the apoptosis induction by anti-
cancer drug.
Phosphorylation of p68 at threonine mediates the effects
of oxaliplatin in the induction of apoptosis
We next investigated whether the p68 threonine phos-
phorylation by p38 plays a role in mediating the effects
of the anti-cancer drug. To this end, the endogenousA
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Figure 4 Effects of p68 phosphorylation on cell apoptosis. (A) HCT116
(p68). HA-p68, wild type and indicated mutants, are expressed in the p68 k
levels of p68 (both endogenous and exogenous). Immunoblot of GAPDH (
viability (C) of the cells in (A) that are treated or untreated with oxaliplatin
cell apoptosis and viability are presented as relative apoptosis and relative
expressing cells without oxaliplatin treatment as 1. Error bars represent stanp68 was knocked down in HCT116 cells. HA-tagged at
p68 or T564/446A was expressed in the p68 knockdown
cells (Figure 4A). The cells were then subsequently trea-
ted by oxaliplatin at a concentration of 10 μM. Cell
apoptosis was measured using a commercially available
apoptosis assay kit (caspase-3 assay). There were no sig-
nificant changes in cell apoptosis without oxaliplatin
treatment. However, oxaliplatin induced apoptosis was
dramatically reduced with the T564/446A expressing
cells. This effect was not observed with the wt p68
expressing cells (Figure 4B). Similar results were
observed with MTT assays (Figure 4C). Thus, we con-
clude that phosphorylation of p68 at T564/446 by p38,
at least partially, mediates the effects of oxaliplatin on
apoptosis induction.
Discussion
In this report, we describe that p68 RNA helicase is phos-
phorylated at T564 and/or T446 in colon cancer HCT116
cells upon the anti-cancer drug oxaliplatin treatment. The
protein is phosphorylated by p38 MAP kinase upon the
drug treatment. The phosphorylation(s) of p68 contributes
to the effects of apoptosis induction by the drug. Our
results echo our previous report that the loss of p68 threo-
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cells are treated by non-targeting siRNA (NT) or siRNA target p68
nockdown cells. Immunoblot of p68 (IB:p68) indicates the cellular
IB:GAPDH) is a loading control. (B) and (C). Cell apoptosis (B) and
are measured by a commercial apoptosis kit (B) or MTT assay (C). The
viability by defining the apoptosis and viability of the vector
dard deviations of four independent experiments.
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T446 may represent a common molecular mechanism
that acts in multiple pathways of apoptosis induction.
It is well established that activation of p38 MAP kinase
is a common pathway for multiple apoptosis inducers, in-
cluding a number of anti-cancer drugs with different mo-
lecular mechanisms [7,13,31], oxidative stresses [8], cells
damaged by UV light [32]. However, the downstream tar-
gets that mediate the effects are not very clear. In fact,
only a few substrates of p38 MAP kinase have been identi-
fied that have a role in cell apoptosis induction, including
p53 [17] and HSP27 [33,34], and the mechanism by which
phosphorylation of these substrates mediates the effects of
apoptosis induction is not fully understood.
How the phosphorylation of p68 at T564 and T446
mediates cell apoptosis is an open question. One plaus-
ible explanation is that the phosphorylated p68 may
change p68 interacting partners in the cells, which
allows p68 to target a particular apoptosis mediating
protein or complex. The consequence for the p68 target-
ing is activation of apoptotic function of the targeted
protein or complex. It is known that a number of DEAD
box RNA helicases associate with apoptosis induction
protein or complex. For example DDX42 modulates the
apoptotic function of ASPP2 by direct interaction with it
[35]. Interaction between GABA receptor associated
protein (GABARAP) and DDX47 is required for induc-
tion of neuronal cell apoptosis [36]. However, it is not
known how this DEAD box RNA helicase regulates the
apoptotic process. In this regard, it will be interesting to
probe whether phosphorylation of p68 at T564 and/or
T446 mediates the association of the protein with a par-
ticular apoptosis inducing complex to activate the com-
plex. Among these potential interacting partners, p53
and p68 interaction is of particular intriguing, p68 was
shown to interact with p53 to mediate the effects of p53
downstream targets. It is also well established that oxali-
platin induces cell apoptosis via activation of p38, which
subsequently phosphorylates p53 in human colorectal
cancer cells [37,38]. Thus, role of existence of p53 func-
tion in apoptosis induction related to the p68 Thr phos-
phorylation is an interesting potential.Methods
Cell culture and antibodies
Human HCT116 cells were obtained from ATCC
(Manassas, VA, USA) and were cultured according to
vendor’s instruction. Antibodies against p68 were raised
against bacterially expressed His-tagged C-terminal do-
main (a.a.437-614) of human p68 (Invitrogen, Carlsbad,
CA, USA, Auburn University Hybridoma Facility). Anti-
bodies against β-actin, phosphor-theronine (14B3), p38
and phosphor-p38, HA-tag, Flag-tag, and GAPDH werepurchased from Santa Cruz, BD Bioscience, and Roche
Applied Science respectively.Drug treatment, DNA constructs, transfections, and siRNA
interference
Oxaliplatin was purchased from Sigma and dissolved in
water to prepare a stock solution of 2.5mM. The stock
solution was stored at −20°C and diluted with medium
to prepare working concentrations. The cDNA of p68
ORF was subcloned into pHM6 vector (Roche) at Hin-
dIII site to get HA-tagged p68 expression vector. The
various p68 single and double threonine mutants (threo-
nine replaced by alanine) were generated by Quick-
Change site-directed mutagenesis kit (Stratagene) and
the mutations were confirmed by DNA sequencing.
P38α cDNA (Origene) was subcloned into p3XFLAG-
myc-CMV™-24 Expression Vector (Sigma). A number of
mutations to get the constitutively active form of p38
were done using the reference [39]. All DNA transfec-
tions were performed using fugene HD (Roche) and
lipofectamine 2000 (Invitrogen) while siRNA transfec-
tions were done with lipofectamine RNAimax (Invitro-
gen). The duplex siRNA against p68 was purchased
from Dharmacon and the sequence was as follows:
siRNA oligonucleotides against p68 (sense: GCAA
GUAGCUGCUGAAUAUUU; antisense: AUAUUCAG
CAGCUACUUGCUU). Cells were transfected with the
indicated plasmids 24 hrs after p68 siRNA knockdown
and further treated with the drug for 24 hrs. The cells
were then harvested for nuclear extract preparation
using a kit from Active motif.Protein expression and purification
The procedure used to express and purify p68 is similar
to the procedure reported previously. P68 ORF was
cloned and various mutants were cloned into expression
vector pET-30a+ using the restriction sites BamHI/
HindIII and transformed into E.coli BL21-CodonPlus
bacteria (Stratagene) were used to express protein. The
bacteria were subcultured in fresh st. LB broth till OD
reached between 0.5 to 0.8 units at 600nm and then sub-
sequently induced with 0.5mM IPTG for 18 hrs at 16°C.
The cells were harvested, washed with 1X PBS buffer,
pelleted and stored at −80°C. The cells were then dis-
rupted by one freeze-thaw cycle at −80°C, resuspended
in lysis buffer (50mM Tris–HCl pH 8.0, 300mM NaCl,
1mM DTT, 10mM PMSF, 10% glycerol) and subjected to
lysozyme (0.5mg/ml) digestion. DTT and PMSF were
also added at 1mM final concentration. The cells were
further subjected to ultrasonication and pelleted. After
centrifugation, the expressed protein was found to be
precipitated in the bacterial inclusion bodies (IB). The IB
were dissolved in denaturing buffer containing 8M urea,
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100. The lysate was passed through Ni-NTA column for
purification of recombinant protein by affinity separation
and the column was washed with the denaturing wash
buffer (8M urea, 50mM Tris–HCl pH 8.0, 250mM NaCl,
0.2% Triton-100 and 20mM imidazole pH 8.0). The pro-
tein was finally eluted with elution buffer containing
250mM Imidazole, 8M urea, 50mM Tris–HCl pH 8.0,
250mM NaCl, 0.2% Triton-100, 0.5mM DTT and 10%
glycerol. The eluted protein solution was refolded using
stepwise dialysis procedure (8M→ 6M→ 4M→ 2M→ 0M)
to remove urea using refolding buffer (200mM arginine,
50mM Tris–HCl pH 8.0, 250mM NaCl, 0.2% Triton-100,
0.5mM DTT and 10% glycerol) and preserved in further
15 to 20% glycerol.
In vitro kinase assay
In this assay, about 1μg of purified proteins were added
to the reaction mixture consisting of 200-250ng of
p38α/SAPK2a enzyme (Upstate cell signaling), 10μCi/μl
of [γ-32P]ATP, Magnesium/ATP cocktail (75mM MgCl2
and 500μM ATP in 20mM MOPS, pH 7.2, 25mM β-
glycerol phosphate, 5mM EGTA, 1mM sodium orthova-
nadate and 1mM dithiothreitol) and 5X reaction buffer
(125 mM Tris–HCl, pH 7.5 and 0.1mM EGTA) in a total
volume of 25μl. After incubation at 30°C for 30 mins,
5X loading buffer (Fermentas) was added to stop the re-
action. The samples were then analyzed by running two
10% SDS-PAGE gels. One of the gels was stained with
Coomassie blue staining solution and destained and the
other gel was dried and subjected to autoradiography.
Cell viability and apoptosis assay
Cell viability of HCT116 cells was measured using (3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide)
or MTT (Sigma). 4000 cells were seeded per well of 96
well plate 24 hrs before knockdown and transfection of
p68 and the mutants. Subsequently, 24 hrs after transfec-
tion, the cells were treated with oxaliplatin for 24 hrs.
Next day, reconstituted MTT reagent was added in an
amount equal to 10% of the culture medium volume and
the cells were incubated at 37°C for a further 4 hrs.
The formazan crystals were dissolved by adding MTT
Solubilization solution. Cell viability was measured
spectrophotometrically by reading the absorbance at a
wavelength of 570 nm.
Cells plated on 6 well plates were treated with oxali-
platin after p68 knockdown and transfections and the
activity of caspase-3 was measured using caspase-3/
CPP32 colorimetric assay kit (Biovision Research pro-
ducts). Briefly, after apoptosis induction, the cells were
resuspended in Cell Lysis Buffer for 10 mins and centri-
fuged. 50 μg of proteins were diluted in Cell Lysis Buffer
to which 2X Reaction buffer and 4 mM DEVD-pNAsubstrate were added and incubated at 37°C. The sam-
ples were read at 405 nm using a microtiter plate reader.
The cells were treated with oxaliplatin at previously indi-
cated concentration and time and apoptosis was mea-
sured using FITC Annexin V Apoptosis Detection Kit
(BDbiosciences). The brief description of the procedure
is as follows: The cells were washed twice with cold 1X
PBS after treatment and resuspended in 1X Annexin
Binding Buffer at a final concentration of 1 x 106 cells/ml.
To 1 x 105 cells (100μl) in a 5ml FACS tube, 5μl of FITC
Annexin V and 5 μl of PI were added, gently vortexed and
incubated at room temperature for 15 mins in the dark.
Finally, 400μl of 1X Annexin Binding Buffer was added and
the samples were analyzed by flow cytometry within 1hr.
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